A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia

CompletadoFase 3ClinicalTrials.gov

ID: NCT00274326Tipo: INTERVENTIONALInicio: 1 de may de 2005Fin estimado: 1 de jul de 2007

Traducción no disponible, mostrando original

Resumen

Primary: * To assess the efficacy of SR121463B in correcting hyponatremia in patients with dilutional hyponatremia other than SIADH or cirrhosis Secondary: * To assess the long-term efficacy of SR121463B in maintaining normonatremia in these patients * To assess the safety and tolerability of SR121463B

Descripción detallada

SR121463B is an orally effective non-peptide, potent, and highly selective V2 receptor antagonist causing free water elimination in animals and humans

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Male or Female patients aged 18 higher
Dilutional Hyponatremia with serum sodium between 115 and 132 mmol/L
Ability to give written informed consent (the informed consent may be signed by a legally authorized representative if the patient is unable to sign)

Criterios de exclusión

Presence of known or untreated adrenal insufficiency, SIADH or cirrhosis, or hyperthyroidism
Presence of signs of hypovolemia
Administration of other V2 receptor antagonists or demeclocycline or lithium within one month and urea within two days prior to study drug administration
Presence of uncontrolled diabetes with fasting glycemia ³ 200 mg/dL (³ 11.09 mmol/L)
Patients considered by the Investigator unsuitable candidates to receive an investigational drug (e.g., presence of any neurological symptoms that may worsen in five days, based on the judgment of the Investigator, or presence of any neurological symptoms for which the persistence of hyponatremia over several days may be deleterious)
Administration of inducers of CYP3A4 (phenobarbital, phenytoin, rifampin, Saint John's Wort) or potent and moderate inhibitors of CYP3A4 within two weeks prior to study drug administration
Presence or history of allergic reaction to SR121463B8
Previous study with SR121463B
Inadequate hematological, renal, and hepatic functions: hemoglobin (Hb) \< 9 g/dL, neutrophils \< 1,500/mm3, platelets \< 100,000/mm3, serum creatinine \> 175 mol/L (or clearance of creatinine \< 30 mL/min for sites where Ethics Committees require this parameter), serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 2 x upper limit of normal (ULN)
QTCB 500 ³ ms
Positive pregnancy test and absence of medically approved contraceptive methods (e.g., surgical sterilization of more than one month duration, oral contraception or intrauterine device in combination with either diaphragm, condom, or spermicide) for females of childbearing potential
Pregnancy or breast-feeding

Intervenciones

drug

SR121463B

Ubicaciones

Sanofi-Aventis Administrative Office

Buenos Aires, Argentina

Patrocinadores

PrincipalSanofi

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Multicenter, Randomized, Placebo-Controlled, Double-Bli... | EligiMed